Prevalence of Pseudomonas aeruginosa in cholesteatoma patients in tertiary care hospital in North India

Abstract

<p class="abstract"><strong>Background:</strong> <span lang="EN-IN">Chronic suppurative otitis media (CSOM) is middle ear infection that lasts for more than three months and is accompanied by a perforation of tympanic membrane. Cholesteatoma is a well know complication of CSOM. Prevalence of CSOM varies between racial and socioeconomic groups. The aim of present study was to determine the principal bacteria in ear discharge in patients with cholesteatoma. </span></p><p class="abstract"><strong>Methods:</strong> <span lang="EN-IN">This was a prospective study conducted in department of ENT in tertiary care hospital and medical college in north India from March 2017 to May 2017.Total 80 patients attended ENT OPD with complain of ear discharge and deafness during the study period, but only 47 patients were clinically diagnosed unsafe type of CSOM or cholesteatoma. Ear swabs were collected and send for microbiology laboratory for bacteriological process.  </span></p><p class="abstract"><strong>Results:</strong> <span lang="EN-IN">Out of 80 patients, 47(58.75%) were clinically diagnosed cholesteatoma and of 29(61.70%) were male and 18(38.29%) were female. Most commonly affected age group was between 10 to 20 year (40.42%) followed by 21 to 30 (21.27%). More than 60 Year was less affected by cholesteatoma. Most common isolated organism was <em>Pseudomonas aeruginosa</em> (66.66%) followed by <em>Klebsiella pneumonia</em> (19.44%) and we used <em>Piperacillin tazobactum</em> and amikacin, and ciprofloxacin in all cases in perioperative period and noticed good response and modified radical mastoidectomy was done in all patients. </span></p><p class="abstract"><strong>Conclusions:</strong> <em><span lang="EN-IN">P. aeruginosa</span></em><span lang="EN-IN"> was found to be the most common isolate in CSOM with cholesteatoma case and piperacillin-tazobactum, amikacin, and ciprofloxacin was found to be cost effective antibiotics.</span></p>